Urinary Tract Infections (UTIs): Symptoms, Diagnosis, and Treatment

Understanding UTIs

UTIs are among the most common bacterial infections, affecting ~50–60% of women and ~12% of men lifetime. Prompt treatment prevents complications (pyelonephritis, sepsis).

Anatomy and Risk Factors

  • Female anatomy: Short urethra (4 cm) near anus → easy bacterial ascent
  • Sexual activity: "Honeymoon cystitis"—mechanical inoculation
  • Menopause: Estrogen loss → vaginal pH ↑, lactobacilli ↓, urethral atrophy
  • Anatomic/functional: Obstruction (stones, BPH, stricture), neurogenic bladder, incomplete emptying
  • Instrumentation: Catheters, cystoscopy
  • Immunosuppression: Diabetes, chemo, steroids
  • Genetics: TLR4, CXCR1 variants affect susceptibility

Pathogens

  • E. coli (75–90% community)
  • Klebsiella, Proteus, Enterococcus, Pseudomonas, Staphylococcus saprophyticus (young women)
  • Fungi (Candida)—catheters, immunocompromised

Clinical Syndromes

  • Urethritis: Dysuria, urethral discharge. Often STI (GC, CT, MG, TV).
  • Cystitis (lower UTI): Dysuria, frequency, urgency, suprapubic pain, hematuria. No fever.
  • Pyelonephritis (upper UTI): Fever, flank pain, CVA tenderness, nausea/vomiting ± cystitis symptoms. Systemic illness.
  • Asymptomatic bacteriuria (ASB): >10⁵ CFU/mL without symptoms. Treat ONLY in pregnancy, pre-urologic procedure. Otherwise → resistance.

Diagnosis

  • Urinalysis: Leukocyte esterase, nitrites, WBC >5/HPF, bacteria
  • Urine culture: Gold standard. ID + susceptibilities. Clean-catch midstream; catheterized if needed.
  • Imaging: Not routine. If recurrent, pyelo, stones, hematuria, failed treatment → US/CT.

Treatment (IDSA/EAU Guidelines)

Uncomplicated Cystitis (Women)

  • Nitrofurantoin 100 mg BID × 5 days (avoid if CrCl <30, G6PD)
  • TMP-SMX DS BID × 3 days (if local resistance <20%)
  • Fosfomycin 3 g single dose
  • Pivmecillinam (non-US)
  • Fluoroquinolones (cipro/levo)—reserve (collateral damage)

Complicated / Pyelonephritis / Men

  • Fluoroquinolones (7–14 days) OR TMP-SMX (14 days) OR β-lactam (ceftriaxone → oral step-down)
  • IV → PO switch when improving
  • Duration: 7 days (complicated cystitis), 14 days (pyelo), longer if bacteremia

Recurrent UTIs (≥3/year or ≥2/6 months)

  • Confirm culture-proven each episode
  • Vaginal estrogen (postmenopausal)—highly effective
  • Prophylaxis: postcoital single dose OR daily low-dose (TMP-SMX, nitrofurantoin, cephalexin) × 6–12 months
  • Methenamine hippurate (non-antibiotic; urine formaldehyde)
  • D-mannose, cranberry (PAC 36 mg)—modest evidence
  • Urology eval if structural concern

Prevention

  • Hydration (2–3 L/day)
  • Void regularly (q3–4h), post-coital
  • Front-to-back wiping
  • Avoid irritants (douches, sprays, spermicides)
  • Condoms (reduce bacterial inoculation)
  • Probiotics (L. crispatus, L. rhamnosus)—emerging evidence

UTIs are treatable. Recurrent UTIs deserve a systematic workup—not just repeated antibiotics.

Urinary Disorders - Related Articles